Project cooperationUpdated on 9 December 2025
Organoid and hiPSc based NAMs
Stem Cell and Organoid Unit Head at Centre for Genomic Regulation
Barcelona, Spain
About
The Tissue Engineering Unit is expert in phenotypically relevant patient derived human in vitro modeling using Organoid and hiPSc derived systems in disease, human development and specific drug treatment. The Unit combines expertise in hiPSc/organoid differentiation with drug testing, CRISPR/Cas9 gene editing and advanced readout strategies such as Bioimaging, scRNAseq and omics anayses.
Similar opportunities
Project cooperation
Collaboration: NAMs to advance biomedical research
- Partner seeks Consortium/Coordinator
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-06: Support to European Research Area (ERA) action on accelerating New Approach Methodologies (NAMs) to advance biomedical research and testing of medicinal products and medical devices
Sarka Lehtonen
Research Director at A.I.Virtanen Institute for Molecular Sciences
Kuopio, Finland
Project cooperation
- Partner seeks Consortium/Coordinator
Simone Mayer
Professor at Karlsruhe Institute of Technology
Karlsruhe, Germany
Project cooperation
Regenerative medicine ATMPs for T1D
- Consortium/Coordinator seeks Partners
- Partner seeks Consortium/Coordinator
- DESTINATION 6: HORIZON-HLTH-2026-01-IND-03: Regulatory science to support translational development of patient-centred health technologies
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-05: Pilot actions for follow-on funding: Leveraging EU-funded collaborative research in regenerative medicine
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-07: Establishing a European network of Centres of Excellence (CoEs) for Advanced Therapies Medicinal Products (ATMPs)
András Dinnyés
Co-founder and General Director at BioTalentum
Godollo, Hungary